Zhongguo aizheng zazhi (Mar 2023)

Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022

  • ZENG Cheng, ZHANG Jian

DOI
https://doi.org/10.19401/j.cnki.1007-3639.2023.03.006
Journal volume & issue
Vol. 33, no. 3
pp. 235 – 240

Abstract

Read online

Pancreatic cancer is a type of malignant tumor with high incidence and low survival rate. It is urgent to develop novel and efficient therapeutic means for patients lacking surgical indications and patients with poor effects of radiotherapy and chemotherapy. In recent years, antibody-drug conjugate (ADC) has become hot because of their high selectivity and anti-tumor activity. ADC has achieved some results in the treatment of pancreatic cancer, but still face many challenges. This article provided a brief review of the latest developments of ADC in pancreatic cancer in 2022.

Keywords